(Q58694467)

5

Vasco Azevedo

0 references

Anderson Miyoshi

3

Anderson Miyoshi

0 references

Clarissa Santos Rocha

4

Clarissa Santos Rocha

0 references

Jean Guy LeBlanc

6

Jean Guy LeBlanc

0 references

Silvina Del Carmen

1

Silvina del Carmen

0 references

author name string

Alejandra de Moreno de LeBlanc

Creative Commons Attribution 3.0 Unported

2

0 references

publication date

2011

0 references

published in

Ulcers

0 references

volume

2011

0 references

page(s)

1-13

0 references

copyright license

start time

27 December 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Inflammatory bowel disease: clinical aspects and established and evolving therapies

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Effects of probiotic on intestinal mucosa of patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Lactobacillus rhamnosus GG decreases TNF-alpha production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Probiotics: a novel approach in the management of food allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Pouchitis: result of microbial imbalance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Probiotics for the treatment of postoperative complications following intestinal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Role of intestinal microflora in chronic inflammation and ulceration of the rat colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Mucosal flora in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Probiotics in inflammatory bowel disease: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Microbial-gut interactions in health and disease. Probiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Bacteriocins of lactic acid bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Functional Cooperation between Interleukin-17 and Tumor Necrosis Factor-α Is Mediated by CCAAT/Enhancer-binding Protein Family Members

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Involvement of dendritic cells in the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

From cheese to pharma: a designer probiotic for IBD

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Erratum: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Interleukin-10-deficient mice develop chronic enterocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of gammadeltaT and regulatory T cells of intestinal intraepithelial lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Health, probiotics, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Therapeutic targeting of toll-like receptors in gastrointestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Toll-like receptors as therapeutic targets in gastrointestinal diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Proposed model: mechanisms of immunomodulation induced by probiotic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Lactobacilli stimulate the innate immune response and modulate the TLR expression of HT29 intestinal epithelial cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Rationale for probiotic treatment strategies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

TLR4 signalling in the intestine in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Gut immune stimulation by non pathogenic Gram(+) and Gram(-) bacteria. Comparison with a probiotic strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Homeostatic effects of TLR9 signaling in experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

The involvement of oxygen radicals in microbicidal mechanisms of leukocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Protein oxidation in aging, disease, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease--radicals or ridiculous?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Antioxidant properties of probiotics and their protective effects in the pathogenesis of radiation-induced enteritis and colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Oral administration of a catalase-producing Lactococcus lactis can prevent a chemically induced colon cancer in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Production of a heterologous nonheme catalase by Lactobacillus casei: an efficient tool for removal of H2O2 and protection of Lactobacillus bulgaricus from oxidative stress in milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651

Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F841651